Portfolio Lab

CONMED Corp

  • Stock
  • Ticker CNMD
  • ISIN US2074101013
  • NYSE

Health care · Medical technology · USA

$46.56 +0.39%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of CONMED Corp since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

CNMDGlobal equities (VT)

$10,000 grew to $11,013. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −78.7% in 06/2026, measured from the peak in 11/2021. The old peak has not been reached again yet.

1-year return
+14.6%
5-year return p.a.
−19.4%
10-year return p.a.
+1.0%
Volatility p.a.
36.7%
Largest decline
−78.7%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end09/202412/202403/202506/202509/202512/202506/202609/2026
Income statement
Revenue317346321342338373343336
Gross profit179198178188166218197189
Operating income6652163812373637
EBITDA705720431641–41
Net income49346.0212.9172320
Earnings per share1.571.080.190.690.090.540.770.66
Balance sheet
Total assets2,3162,3062,2982,3282,3222,3262,3002,304
Liabilities1,3831,3441,3201,3261,3141,2931,2591,245
Equity9339639781,0031,0081,0331,0411,060
Cash3824353439413748
Cash flow
Operating cash flow514342295446–49
Capital expenditure-3.4-4.0-3.8-5.7-5.2-5.1–-2.7
Free cash flow483938234841–47

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2019 at +75.7%, weakest 2025 at −40.0%. 6 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
28 Oct 2026$0.66
29 Jul 2026$0.77
17 Feb 2026$0.54
6 Nov 2025$0.09
31 Jul 2025$0.69
1 May 2025$0.19
18 Feb 2025$1.08
31 Oct 2024$1.57
1 Aug 2024$0.96
25 Apr 2024$0.63
28 Feb 2024$1.05
26 Oct 2023$0.50

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€1.3bn
Market cap in trading currency
$1.39bn
Enterprise value
$1.34bn
P/E
–
P/S
–
P/B
1.31
EV/Sales
–
EV/EBITDA
–
Earnings yield
–
FCF yield
–

Results (last four quarters)

Revenue
–
Gross profit
–
EBITDA
–
Net income
–
Earnings per share
–
Revenue per share
–
Revenue growth
−0.7%
Earnings growth
+592.4%

Profitability

Gross margin
–
Operating margin
–
Net margin
–
Return on equity
–
Return on assets
–

Balance sheet and cash flow

Cash
$48.0m
Cash per share
$1.61
Financial debt
–
Debt/equity %
–
Current ratio
1.49
Book value per share
$35.56
Operating cash flow
–
Free cash flow
–

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
–
Ex-dividend date
15 Sep 2025

Shares and trading

Shares outstanding
29.8m
Volume
384,262
Avg. volume 3 months
362,049
Relative volume
1.1

Price and technicals

Price
$46.56
1 day
+0.4%
52-week high
$53.66
52-week low
$32.11
Distance to 52-week high
−13.2%
Distance to 52-week low
+45.0%
Distance to 50-day line
−1.4%
Distance to 200-day line
+10.6%
RSI (14)
43
Volatility 1M
56.7%

Performance

1 week
−8.0%
1 month
−5.8%
3 months
−9.6%
6 months
+25.1%
YTD
+14.7%
1 year
+14.9%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has CNMD performed since 11/2016?

$10,000 grew to $11,013 by 20 Nov 2026, which is +1.0% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is CNMD?

Volatility was 36.7% per year, measured on monthly returns. The largest decline from a peak was −78.7%, with the low in 06/2026.

How does CNMD compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, CNMD returned +1.0% at 36.7%. The correlation of monthly returns was 0.53; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

CONMED Corp (CNMD): Return and risk | Portfolio Lab